Cumulus Neuroscience

Saturday March 8th is International Women’s Day 2025. At Cumulus Neuroscience, nearly 50% of employees are women, including #WomenInSTEM across our Science, Analytics, Engineering, Regulatory & Quality, Business Development & Customer Success teams. We celebrate these talented women and all of the allies at Cumulus and beyond who support them! #IWD2025 #AccelerateAction

George Stothart, PhD, Principal Scientist at Cumulus Neuroscience and Senior Lecturer at the University of Bath had an opportunity to showcase his novel Alzheimer’s screening tool AccelADx when Government Chief Scientific Adviser Professor Dame Angela McLean DBE FRS visited the university last week. Read more: https://lnkd.in/eM5-W48R Professor Dame Angela McLean: https://lnkd.in/eTYehRkQ George Stothart: https://lnkd.in/ed5qRQc7 Image credit: Tim Gander / University of Bath

Join the Cumulus Neuroscience Executive Team for the 8th Annual Neuroscience Innovation Forum at the Marine Memorial Club in San Francisco on Sunday January 12th where Co-Founder and CSO Brian Murphy, PhD will present an overview of our NeuLogiq neuro-assessment platform and our new product in development, AccelADx which has the potential to revolutionize how the earliest signs of Alzheimer's are detected. #CNS #alzheimers #innovation Tina Sampath, Interim CEO Siggi Saevarsson, COO

Brian Murphy, PhD, Co-founder and CSO of Cumulus Neuroscience presented a podium presentation titled “EEG for Everyone - Objective Measure of EEG and Cognition at Scale with the NeuLogiq Platform” and a poster titled “Scalable tools for the non-invasive measurement of neuroplasticity in clinical trials of CNS therapies” at the International Pharmaco-EEG Society for Preclinical and Clinical Electrophysiological Brain Research (IPEG) annual meeting in Izmir, Turkey last week. As EEG and digital measures of behaviour emerge as a key markers in CNS trials, we presented data demonstrating that the platform can be used at scale with a variety of populations to detect the symptomology and mechanisms of disease and therapies in neurology and psychiatry. https://lnkd.in/ecc6RqMS

Cumulus Neuroscience is excited to announce that Brian Murphy, PHD, CSO and Co-founder of Cumulus was featured on the Shot of Digital Health Therapy podcast where he discussed his circuitous journey to becoming a computational neuroscientist, and ultimately how his lack of patience and a desire to measure the brain at scale led him to launch Cumulus. Hosted by digital health veterans Jim Joyce and Eugene Borukhovich, this weekly “meticulously unproduced” podcast features leaders in the field of digital health. Podcast links: Youtube: https://lnkd.in/eGQnPZyW Podcast: https://lnkd.in/dkQ55Rh https://lnkd.in/eZDeAVPi https://lnkd.in/ebY_GJSu

Dementia and Alzheimer’s disease represent a leading cause of death in the UK. There are over 900,000 patients living with dementia in the UK today and as many of you know, there is no cure. Our team is committed to addressing this unmet need by working alongside biopharma to accelerate the development of a new generation of therapies. Importantly, our commitment extends outside the office through participation in local events focused on raising awareness and much needed funding. This year, our small but mighty team raised over £1100+ ($1400+ US) for the Belfast Memory Walk 2024! #MemoryWalk #EndAlzheimers

Cumulus Neuroscience values our strategic partnership with the Digital Medicine Society (DiMe) - join our Co-Founder and CSO Brian Murphy, PhD at 11 AM ET on November 14th for this important launch event where new core digital clinical measures for use in Alzheimer’s Disease and related dementias research will be discussed, along with related resources. #endalzheimers #digitalmeasures #digitalendpoints

We are excited to share the official Bio-Hermes 2 press release issued last week by the Global Alzheimer's Platform Foundation announcing strategic study partners including Cumulus Neuroscience. We look forward to validating AccelADx™, our novel AI-enabled screening tool that provides an objective measure of memory impairment alongside other digital and blood-based biomarkers. It’s inspiring to see so many companies in this space working collectively to accelerate the development of much needed tools to enable earlier diagnosis. Click here to learn more: https://lnkd.in/gBB5pb_P #EndAlzheimers #GAPFoundation #digitalmeasures #digitalbiomarkers

November is National Alzheimer’s Disease Awareness Month. Cumulus Neuroscience is honored to be a strategic partner in the Global Alzheimer's Platform Foundation Bio-Hermes 2 study where the focus is on advancing the science for everyone – regardless of race or ethnicity. AccelADx™, our novel screening tool that provides an objective measure of memory impairment, will be validated against blood-based and digital biomarkers across an ethnically diverse group of patients. #EndAlzheimers #GAPFoundation #digitalmeasures #digitalbiomarkers

Meet Shannon Diggin. Since joining Cumulus Neuroscience in 2021, she has earned her CCRP (Certified Clinical Research Professional) certification recognizing expertise in clinical trial coordination and management, and has led the execution of our largest internal study (CNS-101), investigating the usability of the NeuLogiq™ platform in patients with Alzheimer's disease across seven sites in the UK. “Being part of Cumulus means being at the forefront of innovative research that has the potential to transform lives. I have the opportunity to work and collaborate with a passionate team dedicated to advancing neuroscience and pushing the boundaries of what’s possible in clinical trials. Through my role, I contribute to meaningful projects that not only challenge me professionally but also align with my commitment to improving patient outcomes. Cumulus embodies a culture of curiosity and support, where every voice matters, and together, we are paving the way for more accurate, timely interventions that can truly improve patient outcomes on a global scale.”